Sort
10,766 grants matching “checkpoint inhibitor”
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
$24,146Heide L Ford · University Of Colorado Denver · R01 · FY2018 · CA
Regulation of inhibitory DAMP to harness immunogenic cell death
$24,057Kazukuni Hayashi · Cedars-Sinai Medical Center · F31 · FY2022 · CA
Small-molecule Inhibition of Glycogen Synthase Kinase-3 Sensitizes Colorectal Cancer Cells and Stimulates Immune Cells to Bolster Immune Cell-mediated Tumor Cytotoxicity
$23,930Kelsey Elizabeth Huntington · Brown University · F31 · FY2023 · CA
A new immune checkpoint pathway in human bladder cancer
$23,779Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2023 · CA
Targeted radionuclide therapy for tumor immunomodulation and enhancing immunotherapy response
$23,687Caroline Paula Anne Kerr · University Of Wisconsin-Madison · F30 · FY2025 · CA
Rebalancing protein homeostasis enhances tumor antigen presentation
$23,322Grissel Cervantes Jaramillo · Massachusetts Institute Of Technology · F31 · FY2022 · CA
25 Cancer Genetics and Epigenetics
$23,220Richard D Wood · University Of Tx Md Anderson Can Ctr · P30 · FY2024 · CA
07 Gastrointestinal Cancers
$23,220Scott Kopetz · University Of Tx Md Anderson Can Ctr · P30 · FY2024 · CA
11 Prostate Cancer
$23,220Christopher J. Logothetis · University Of Tx Md Anderson Can Ctr · P30 · FY2024 · CA
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation
$23,201Dmitriy Zamarin · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
The role of PTEN in DNA metabolism and replication
$23,047Abigail Rose Lubin · Icahn School Of Medicine At Mount Sinai · F31 · FY2023 · CA
Advancing Mechanistic Concepts of FGFR1-Regulated Adaptive PDL1 Expression in HNSCC
$22,868Jacqueline Mann · University Of Michigan At Ann Arbor · F31 · FY2019 · DE
Targeting Cell Cycle Machinery For Cancer Therapy
$22,858E Premkumar Reddy · Temple Univ Of The Commonwealth · R01 · FY2008 · CA
Characterization of a novel suppressor of oncogenic CARD11 signaling.
$22,799Nicole Marie Carter · Johns Hopkins University · F31 · FY2023 · CA
Discovery of protein-protein interaction inhibitors of Replication Protein A
$22,784James Patrone · Vanderbilt University · F32 · FY2015 · CA
The effect of hydroxychloroquine treatment on immune checkpoint inhibitors
$22,685Tim Greten · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
The Study of Immune Effects in Gliomas Treated with Oncolytic Viruses in Combination with IDO Inhibitors
$22,058Teresa T Nguyen · University Of Tx Md Anderson Can Ctr · F31 · FY2021 · CA
Fhit as modulator of Chk1 termination and response to DNA-damaging agents
$21,959Joshua Saldivar · Ohio State University · F31 · FY2012 · CA
Dietary nutrient zeaxanthin enhances anti-tumor immunity by reprogramming CD8+ T cell function
$21,582Freya Qi Zhang · University Of Chicago · F31 · FY2025 · CA
Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors
$21,054Ashish Ranjan · Oklahoma State University Stillwater · R01 · FY2023 · CA
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
$21,034Andrew Sikora · University Of Tx Md Anderson Can Ctr · U01 · FY2022 · DE
Sensitizing High Grade Serous Cancers to Immunotherapy through the Induction of DNA Damage
$20,968Karen McLean · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Determining Dendritic Cell Responses to Vaccine-based Immunotherapy in PDAC at Single Cell Resolution.
$20,581Dimitrios N Sidiropoulos · Johns Hopkins University · F31 · FY2023 · CA
CORRELATIVE SCIENCE CORE
$20,549Jon C Aster · Dana-Farber Cancer Inst · P50 · FY2021 · CA
Is ERBB4 a Driver of BRAF WT Melanomas?
$20,349David J. Riese · Auburn University At Auburn · R15 · FY2024 · CA